To the full analysis
Buyback calculator for Dr. Reddy's Laboratories
Dr. Reddy's Laboratories stock: key metrics
RDYDr. Reddy's Laboratories had an operating margin of 13.8% and a return on invested capital (ROIC) of 11% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 47.4% | 17.2% | 14.3% |
| 2008 | 50.8% | 6.7% | 9.4% |
| 2009 | 52.6% | −4.1% | −7.4% |
| 2010 | 51.7% | 2.9% | 1.5% |
| 2011 | 53.9% | 16.9% | 14.8% |
| 2012 | 55.1% | 18.9% | 14.7% |
| 2013 | 52.1% | 18.2% | 14.4% |
| 2014 | 57.4% | 19.7% | 16.3% |
| 2015 | 57.6% | 17.7% | 15.0% |
| 2016 | 59.6% | 19.1% | 12.9% |
| 2017 | 55.6% | 9.6% | 8.5% |
| 2018 | 53.7% | 8.4% | 6.9% |
| 2019 | 54.2% | 13.6% | 12.2% |
| 2020 | 53.8% | 9.2% | 11.2% |
| 2021 | 50.8% | 16.9% | 9.1% |
| 2022 | 53.1% | 13.7% | 11.0% |
| 2023 | 56.7% | 23.2% | 18.3% |
| 2024 | 58.6% | 24.3% | 19.9% |
| 2025 | 58.5% | 22.1% | 17.4% |
| 2026 | 52.8% | 13.8% | 12.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 22.4% | 20.6% | 10.9% |
| 2008 | 9.9% | 6.5% | 5.5% |
| 2009 | −12.3% | −4.1% | −6.2% |
| 2010 | 2.5% | 2.0% | 1.3% |
| 2011 | 24.0% | 20.2% | 11.6% |
| 2012 | 24.8% | 20.8% | 11.9% |
| 2013 | 2.3% | 3.4% | 1.2% |
| 2014 | 23.7% | 4.3% | 12.6% |
| 2015 | 19.9% | 19.1% | 11.4% |
| 2016 | 15.6% | 18.5% | 9.6% |
| 2017 | 9.7% | 8.0% | 5.5% |
| 2018 | 7.8% | 5.2% | 4.3% |
| 2019 | 13.4% | 11.3% | 8.3% |
| 2020 | 200.0% | 20.5% | 200.0% |
| 2021 | 9.8% | 13.1% | 6.4% |
| 2022 | 12.4% | 23.6% | 8.0% |
| 2023 | 19.5% | 23.5% | 14.0% |
| 2024 | 19.8% | 26.1% | 14.4% |
| 2025 | 17.0% | 19.7% | 11.5% |
| 2026 | 12.2% | 11.0% | 7.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 10 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.